News
TIL
7.68
+1.59%
0.12
Weekly Report: what happened at TIL last week (0615-0619)?
Weekly Report · 2d ago
Weekly Report: what happened at TIL last week (0608-0612)?
Weekly Report · 06/15 10:07
Instil Bio Shareholders Back Directors and Auditor at Meeting
TipRanks · 06/11 22:18
Instil Bio shareholders ratify RSM US LLP as auditor for 2026
PUBT · 06/11 20:31
Weekly Report: what happened at TIL last week (0601-0605)?
Weekly Report · 06/08 10:03
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 06/03 21:07
Weekly Report: what happened at TIL last week (0525-0529)?
Weekly Report · 06/01 10:07
Allogene names Zachary Roberts CEO, succeeding David Chang effective July 1, 2026
PUBT · 05/28 21:02
Weekly Report: what happened at TIL last week (0518-0522)?
Weekly Report · 05/25 10:09
Weekly Report: what happened at TIL last week (0511-0515)?
Weekly Report · 05/18 10:09
Instil Bio Non-GAAP EPS of -$0.32
Seeking Alpha · 05/15 11:12
Earnings Scheduled For May 15, 2026
Benzinga · 05/15 11:11
Instil Bio Q1 net loss narrows on lower R&D expenses
Reuters · 05/15 11:07
Instil Bio Q1 FY26 net loss narrows to $4.2 million from year-earlier $28.2 million
PUBT · 05/15 11:01
*Instil Bio 1Q Loss/Shr 62c >TIL
Dow Jones · 05/15 11:01
INSTIL BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 05/15 11:00
Press Release: Instil Bio Reports First Quarter -2-
Dow Jones · 05/15 11:00
Press Release: Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 05/15 11:00
Weekly Report: what happened at TIL last week (0504-0508)?
Weekly Report · 05/11 10:07
Weekly Report: what happened at TIL last week (0427-0501)?
Weekly Report · 05/04 10:05
More
Webull provides a variety of real-time TIL stock news. You can receive the latest news about Instil Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TIL
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.